62 results
FWP
KPRX
Kiora Pharmaceuticals Inc
14 Jul 22
Free writing prospectus
5:14pm
effects ▪ Safety concerns: severe liver injury & other adverse events ▪ Black box warning: risk of severe liver injury Aubagio (teriflunomide) Approved … Ƒ 7 u‹;‹;7bv;-v; ▪ Persistent Corneal Epithelial Defects (PCED) ˃ Defined by a failure of rapid epithelialization and closure of a corneal injury
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
27 May 21
Regulation FD Disclosure
7:01am
effects – Safety concerns of severe liver injury and other adverse events – Black box added regarding the risk of severe liver injury Aubagio still … with facial burns have ocular injury 1 OBG accelerates the healing of the epithelium – OBG demonstrated acceleration of wound healing in patients
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
14 Sep 21
Regulation FD Disclosure
4:20pm
selectivity and potency results in off - target side effects – Safety concerns of severe liver injury and other adverse events – Black box added … regarding the risk of severe liver injury Aubagio still achieved revenue ~$2.5B in 2020 1. Most recent public sources available from April 2021 Company
8-K
EX-10.1
KPRX
Kiora Pharmaceuticals Inc
1 Feb 22
Kiora Pharmaceuticals Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from Board
6:45am
that you have not suffered an injury in the workplace which has not been reported to the Company and are not aware of any facts or circumstances … that would give rise to a claim that you suffered a workplace injury. You acknowledge that you have received any leaves of absence and any reasonable
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
11 Jan 22
Regulation FD Disclosure
12:00am
selectivity and potency results in off - target side effects ▪ Safety concerns of severe liver injury and other adverse events ▪ Black box added … regarding the risk of severe liver injury PTC Therapeutics PTC299 Ph1b AML Ph2/3 COVID - 19 Immunic IMU - 838 Ph2/3 UC, MS, CD ASLAN ASLAN003 Ph2 autoimmune
8-K
EX-10.2
e98zot
15 Jun 23
Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
4:59pm
8-K
EX-99.1
rnh98
12 Dec 18
Regulation FD Disclosure
4:30pm
8-K
EX-10.1
pxu 2j6o8c2hjbimo5g
3 Dec 19
Departure of Directors or Certain Officers
6:55am
FWP
rz7oaoeap2qi pf5
15 May 23
Free writing prospectus
5:18pm
424B3
5w8vx ky0ohws4
28 Dec 22
Prospectus supplement
4:48pm
424B1
2jblowdsoa ijpxqm55
2 Jun 23
Prospectus with pricing info
5:08pm
424B3
jp3hp jqq3t
18 Nov 19
Prospectus supplement
4:53pm
424B1
fu746z
22 Jul 22
Prospectus with pricing info
6:00pm